Reveromycin B

• UNSPSC Description:

  Reveromycin B is a spiroketal bacterial metabolite originally isolated from Streptomyces. It inhibits EGF-induced mitogenic activity in Balb/MK cells (IC50=6 μg/mL) and exhibits pH-dependent antifungal activity against C. albicans (MICs=15.6 and >500 μg/mL at pH 3.0 and 7.4, respectively). Unlike reveromycin A and reveromycin C, reveromycin B does not inhibit proliferation of KB and K562 cells.

• Target Antigen:

  Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/reveromycin-b.html

• Smiles:

  CC(/C=C/[C@H](O)[C@@H](C)/C=C/C(O)=O)=C\C[C@H]1O[C@]2(CC[C@@H]1C)CC[C@@](CCCC)(O2)[C@@H](OC(CCC(O)=O)=O)/C=C/C(C)=C/C(O)=O

• Molecular Weight:

  660.79

• References & Citations:

  [1]Takahashi, et al. Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities. J. Antibiot. (Tokyo) 45(9), 1414-1419 (1992).

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  144860-68-4